Amol Tandon

2.4k total citations · 1 hit paper
16 papers, 2.0k citations indexed

About

Amol Tandon is a scholar working on Oncology, Molecular Biology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Amol Tandon has authored 16 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 5 papers in Molecular Biology and 5 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Amol Tandon's work include HER2/EGFR in Cancer Research (6 papers), Monoclonal and Polyclonal Antibodies Research (5 papers) and Radiopharmaceutical Chemistry and Applications (3 papers). Amol Tandon is often cited by papers focused on HER2/EGFR in Cancer Research (6 papers), Monoclonal and Polyclonal Antibodies Research (5 papers) and Radiopharmaceutical Chemistry and Applications (3 papers). Amol Tandon collaborates with scholars based in United States, Germany and Switzerland. Amol Tandon's co-authors include Gary M. Clark, Gary C. Chamness, Suzanne A.W. Fuqua, Axel Ullrich, William McGuire, Daniel R. Ciocca, D. Craig Allred, William J. Welch, Helgi Sigurðsson and Mårten Fernö and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Scientific Reports.

In The Last Decade

Amol Tandon

15 papers receiving 2.0k citations

Hit Papers

HER-2/neu oncogene protein and prognosis in breast cancer. 1989 2026 2001 2013 1989 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. HER-2/neu oncogene protein and prognosis in breast cancer.
    1989 497 citations Amol Tandon, Gary M. Clark et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Amol Tandon United States 11 1.4k 887 700 506 199 16 2.0k
Anne E.G. Lenferink Canada 18 1.1k 0.8× 1.3k 1.4× 423 0.6× 280 0.6× 233 1.2× 43 2.0k
Kerstin Borgmann Germany 32 1.2k 0.9× 1.8k 2.0× 504 0.7× 712 1.4× 497 2.5× 85 2.7k
Katrien Berns Netherlands 15 1.2k 0.9× 2.2k 2.5× 417 0.6× 537 1.1× 343 1.7× 19 3.0k
M H Kraus United States 15 1.8k 1.4× 1.5k 1.7× 1.2k 1.7× 192 0.4× 219 1.1× 17 2.5k
Takashi Imai Japan 26 505 0.4× 914 1.0× 631 0.9× 345 0.7× 444 2.2× 78 2.0k
Markus Münz Germany 12 1.0k 0.8× 1.0k 1.1× 269 0.4× 372 0.7× 131 0.7× 18 1.9k
E. Marielle Hijmans Netherlands 17 1.7k 1.2× 2.5k 2.8× 408 0.6× 518 1.0× 382 1.9× 20 3.4k
Sarajane Ross United States 23 1.2k 0.9× 2.0k 2.3× 883 1.3× 327 0.6× 524 2.6× 37 3.1k
Oreste Segatto United States 31 2.0k 1.5× 1.9k 2.1× 1.2k 1.7× 357 0.7× 269 1.4× 55 3.4k
Kendall D. Carey United States 10 1.1k 0.8× 951 1.1× 651 0.9× 121 0.2× 373 1.9× 12 1.9k

Countries citing papers authored by Amol Tandon

Since Specialization
Citations

This map shows the geographic impact of Amol Tandon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amol Tandon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amol Tandon more than expected).

Fields of papers citing papers by Amol Tandon

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amol Tandon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amol Tandon. The network helps show where Amol Tandon may publish in the future.

Co-authorship network of co-authors of Amol Tandon

This figure shows the co-authorship network connecting the top 25 collaborators of Amol Tandon. A scholar is included among the top collaborators of Amol Tandon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amol Tandon. Amol Tandon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Tandon, Amol, A. K. Jissy, & Vaibhav Dubey. (2023). Translocation Tales: Unraveling the MYC Deregulation in Burkitt Lymphoma for Innovative Therapeutic Strategies. MDPI (MDPI AG). 1(2). 97–117. 2 indexed citations
2.
3.
Mallik, Sanchari Basu, et al.. (2023). Small Molecule Anti-Inflammatory TYK2 Inhibitors Attenuate Inflammation and Clinical Symptoms in a Mouse Model of Imiquimod Induced Psoriasis. Journal of Pharmacology and Experimental Therapeutics. 385. 497–497.
4.
Tandon, Amol, et al.. (2020). ADP-dependent glucokinase as a novel onco-target for haematological malignancies. Scientific Reports. 10(1). 13584–13584. 3 indexed citations
5.
Tandon, Amol, Michael Carl, Nastassja Himmelreich, et al.. (2019). ADP-dependent glucokinase regulates energy metabolism via ER-localized glucose sensing. Scientific Reports. 9(1). 14248–14248. 18 indexed citations
6.
Mleczko‐Sanecka, Katarzyna, et al.. (2017). Cellular citrate levels establish a regulatory link between energy metabolism and the hepatic iron hormone hepcidin. Journal of Molecular Medicine. 95(8). 851–860. 9 indexed citations
7.
Ravdin, Peter M., Amol Tandon, D. Craig Allred, et al.. (1994). Cathepsin D by western blotting and immunohistochemistry: failure to confirm correlations with prognosis in node-negative breast cancer.. Journal of Clinical Oncology. 12(3). 467–474. 47 indexed citations
8.
Molina, Rafael, Daniel R. Ciocca, Amol Tandon, et al.. (1993). Expression of HER-2/neu oncoprotein in human breast cancer: a comparison of immunohistochemical and western blot techniques.. PubMed. 12(6B). 1965–71. 49 indexed citations
9.
Ciocca, Daniel R., Gary M. Clark, Amol Tandon, et al.. (1993). Heat Shock Protein hsp70 in Patients With Axillary Lymph Node-Negative Breast Cancer: Prognostic Implications. JNCI Journal of the National Cancer Institute. 85(7). 570–574. 301 indexed citations
10.
Ciocca, Daniel R., Frank K. Fujimura, Amol Tandon, et al.. (1992). Correlation of HER-2/neu Amplification With Expression and With Other Prognostic Factors in 1103 Breast Cancers. JNCI Journal of the National Cancer Institute. 84(16). 1279–1282. 92 indexed citations
11.
Allred, D. Craig, Gary M. Clark, Amol Tandon, et al.. (1992). HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma.. Journal of Clinical Oncology. 10(4). 599–605. 385 indexed citations
12.
Shi, Shan‐Rong, et al.. (1992). A technique for retrieving antigens in formalin-fixed, routinely acid-decalcified, celloidin-embedded human temporal bone sections for immunohistochemistry.. Journal of Histochemistry & Cytochemistry. 40(6). 787–792. 106 indexed citations
13.
Borg, Åke, Amol Tandon, Helgi Sigurðsson, et al.. (1990). HER-2/neu amplification predicts poor survival in node-positive breast cancer.. PubMed. 50(14). 4332–7. 393 indexed citations
14.
Tandon, Amol, Gary M. Clark, Gary C. Chamness, & William McGuire. (1990). Association of the 323/A3 surface glycoprotein with tumor characteristics and behavior in human breast cancer.. PubMed. 50(11). 3317–21. 43 indexed citations
15.
Tandon, Amol, et al.. (1989). HER-2/neu oncogene protein and prognosis in breast cancer.. Journal of Clinical Oncology. 7(8). 1120–1128. 497 indexed citations breakdown →
16.
Merkel, Douglas E., Suzanne A.W. Fuqua, Amol Tandon, et al.. (1989). Electrophoretic analysis of 248 clinical breast cancer specimens for P-glycoprotein overexpression or gene amplification.. Journal of Clinical Oncology. 7(8). 1129–1136. 74 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Anne E.G. Lenferink Breakdown of academic impact, for papers by Kerstin Borgmann Breakdown of academic impact, for papers by Katrien Berns Breakdown of academic impact, for papers by M H Kraus Breakdown of academic impact, for papers by Takashi Imai Breakdown of academic impact, for papers by Markus Münz Breakdown of academic impact, for papers by E. Marielle Hijmans Breakdown of academic impact, for papers by Sarajane Ross Breakdown of academic impact, for papers by Oreste Segatto Breakdown of academic impact, for papers by Kendall D. Carey
Rankless by CCL
2026